25 results
Thumbnail

- D3.147 - The inhaled PDE4 inhibitor tanimilast shows a broad anti-inflammatory effect in two mouse models of asthma induced by house dust mite

Thumbnail

- D3.148 - Oscillometry and spirometry derived ratios to assess small airways dysfunction in severe asthma patients taking tezepelumab

Thumbnail

D3.149 - Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in a real life clinic setting

Thumbnail

- D3.150 - Effects of benralizumab on T cell adhesion molecules in severe eosinophilic asthma: modulation by IL-25 and IL-33

Thumbnail

- D3.151 - Prevalence and clinical characteristics of adult asthma patients with different phenotype across GINA step 1 to 5 asthma

Thumbnail

D3.152 - Phenotype and treatment response of allergic patients with severe asthma: a real-world experience from Argentina

Thumbnail

- D3.154 - Safety of allergen immunotherapy in patients with severe asthma. A real-world, multicentre, observational retrospective study

Thumbnail

D3.155 - IL-1 signaling pathway molecules as key markers in childhood severe asthma

Thumbnail

- D3.156 - Self-reported asthma symptoms and asthma medication usage in patients with possible asthma: A MASK-air® real-world study

Thumbnail

D3.157 - A study of the detailed patterns of wheeze presence and absence from infancy through to adolescence

Thumbnail

- D3.158 - Clinical and functional profile of children with asthma in a tertiary referral hospital

Thumbnail

D3.159 - Investigation of Huai Qi Huang Granules' Impact and Mechanism on Asthmatic Mice's Antiviral Capability

Thumbnail

- D3.162 - The Effects of Phthalate Exposure on Asthma via Microbiota Changes

Thumbnail

- D3.163 - Mast cell activation test and airway hyperresponsiveness in cat allergy: investigating the link to cat allergen induced asthma

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes